Otsuka Pharmaceutical is launching a virtual study to see if digital therapeutics can reduce depression symptoms.
It’s the next step in a partnership between the Tokyo-based drugmaker and Click Therapeutics, a digital health startup that is developing programs for smoking cessation, depression and insomnia. [Read more…] about Innovation in COVID times: Otsuka and Click Therapeutics announce fully virtual clinical trial, leveraging Verily’s Project Baseline
Brain-wave pattern can identify people likely to respond to antidepressant, study finds (Stanford Medicine press release):
“A new method of interpreting brain activity could potentially be used in clinics to help determine the best treatment options for depression, according to a study led by researchers at the Stanford School of Medicine.
Stanford researchers and their collaborators used electroencephalography, a tool for monitoring electrical activity in the brain, and an algorithm to identify a brain-wave signature in [Read more…] about Machine-learning study finds EEG brain signatures that predict response to antidepressant treatments
Why technology — not medication — is the future of treating older adults with depression (McKnight’s Long-term Care News):
“The go-to treatment for many cases of depression is medication.
Unfortunately, this treatment option can cause as many issues as the problem it is trying to solve. Antidepressants can put residents at greater risk of falls, negative health complications and other poor conditions. Some studies indicate that antidepressants may not be effective for most older Americans. [Read more…] about Could technology help cure depression among older adults? (Short answer: Yes)
Drugs for PTSD linked to increased risk of dementia (The Pharmaceutical Journal):
“Certain psychotropic drugs used to treat post-traumatic stress disorder (PTSD) increase the risk of developing dementia, including in patients who do not have PTSD but take the drugs for other conditions, study results published in the Journal of the American Geriatrics Society [Read more…] about Study: Common medication treatments for PTSD can increase the risk of developing dementia
Time for a new edition of SharpBrains’ eNewsletter, full of fascinating brain studies and emerging thinking and tools for lifelong mental health and performance. Happy reading!
- Dementia rates in the UK significantly lower than forecasted–especially for men–highlighting the protective role of lifestyle and education
- Systematic evidence review finds cognitive behavioral therapy as effective as antidepressant medicines in treating depression
- To boost creativity, combine systematic daily effort with diverse emotional states
- Mindfulness-based Stress Reduction (MBSR) and Cognitive Behavioral Therapy (CBT) beat usual care for chronic back pain
- Landmark study on neural circuits shows that “cells that fire together wire together,” refining the popular “Use it or lose it”
- On “ethical placebos,” Medicine, and Mind/ Body interactions: A book review
- New Nevada regulation requires professional fighters to undergo regular computerized cognitive testing
- Brain Training – Can We Really Enhance Our Cognitive Skills?
- Since more than 50% of people worldwide can’t access appropriate mental health treatments, let’s welcome (and test) mobile health apps
- Footballers (also known as soccer players) add novelty, variety and challenge to sharpen cognitive and perceptual skills
- Brain hacking emerges as latest trend in wearable tech, but is it ready for prime time?
- Maker of “neuro” functional drinks settles false advertising complaint
- French neurotech start-up Rythm raises $11m to help improve sleep quality
- May 17–18th @ San Francisco: Experiential Technology and NeuroGaming Conference
Finally, thank you very much to the 191 registered participants in our very stimulating April 21st virtual lecture. You should already have received access to the full recording and other materials, but please contact us if you have any problem.
Have a great month of May!
The SharpBrains Team
Depression: Treatment Beyond Medication (The Dana Foundation):
“Major depressive disorder affects nearly 7 percent of people in the US aged 18 and up, according to the Depression and Bipolar Support Alliance. Those who seek treatment will most likely be prescribed a second-generation antidepressant medication such as a selective serotonin reuptake inhibitor (SSRI), tricyclic antidepressant (TCA), or a monoamine oxidase inhibitor (MAOI). Some recent studies, though, [Read more…] about Systematic evidence review finds cognitive behavioral therapy as effective as antidepressant medicines in treating depression